Express Scripts moving to performance-based contracts with drug industry, out of carve-outs, exec says.
EXPRESS SCRIPTS SEES MOVE AWAY FROM "ERA OF DISCOUNTING," anticipating more performance-based contracts with the pharmaceutical sector over the next three years, CEO Barrett Toan told analysts at the Alex. Brown health care seminar. The independent PBM covering approximately 9 mil. lives "will be increasingly involved in strategic relationships with the pharmaceutical manufacturing sector" in terms of pharmacy services, Toan said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth